PRNewswire/ – BioAtla ®, LLC, a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic protein therapeutics for the oncology market, today announced that Himalaya Therapeutics SEZC, a Cayman Island corporation and majority owned subsidiary of BioAtla, has the exclusive license from BioAtla to develop and commercialize several specific, differentiated product candidates for the Greater China.
The Himalaya Therapeutics portfolio includes two CAB candidates, CAB-AXL-ADC and CAB-ROR2-ADC, each currently in Phase 1/2 clinical trials conducted by BioAtla at sites in the United States.
Himalaya Therapeutics will participate in BioAtla’s potential Greater China.
Himalaya will also support BioAtla’s global clinical trials effort in Greater China.
Himalaya Therapeutics is expected to fund its operations independent from BioAtla.
These were primary motivating factors for Beijing Sinobioway Group Company and its related investor groups to contribute all of their rights to certain and any future CAB candidates that were part of their 2015 collaboration agreement with BioAtla in exchange for a minority equity position in Himalaya Therapeutics.
BioAtla develops novel monoclonal antibody and other protein therapeutic product candidates designed to have more selective targeting, greater efficacy, and more cost-efficient and predictable manufacturing than traditional antibodies.